Cervical cancer is one of the most common malignant tumors in the female reproductive system. In 2022, approximately 661,000 new cases were reported worldwide, ranking fourth in the incidence of female malignant tumors; in the same year, there were about 150,700 new cases and 55,700 deaths in China, with the incidence showing an increasing trend year by year. The treatment methods for cervical cancer are diverse, mainly including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. For patients with locally advanced cervical cancer (staged ⅠB3, ⅡA2 to ⅣA according to the International Federation of Gynecology and Obstetrics [FIGO] staging system), definitive concurrent chemoradiotherapy is the standard treatment regimen; while patients with early-stage cervical cancer receiving definitive radiotherapy can achieve therapeutic effects comparable to those of surgery. This guideline aims to provide scientific and standardized clinical guidance for radical radiotherapy of cervical cancer in light of China's national conditions.